Primary Peptides Inc

[On Demand]
Primary Peptides Inc is a clinical-stage targeted protein degradation platform technology company based in Vancouver, Canada. We are developing novel peptide therapeutics using two platform technologies: 1) peptide array for identifying, targeting, and disrupting specific protein-protein interactions; 2) peptide-mediated protein knockdown technology that can compete with small molecule PROTAC technology in degrading proteins of interest and can replace antisense and siRNA technology platforms in many indications with greater specificity and greater temporal precision. We have signed 4 pharma partnerships so far. Our 1st lead compound has finished a phase 1 clinical trial in healthy volunteers. The 2nd and 3rd lead compounds are in IND-enabling studies. Our platform technologies are versatile and are capable of rapidly generating lead compounds for a variety of disease indications. We are looking for partners (VC and pharma) to advance our platform.
Company Type:
Privately Funded Company
Company HQ State:
British Columbia
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
K13 peptide for stroke
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Primary Peptides Inc